Insider Transactions in Q2 2022 at Ani Pharmaceuticals Inc (ANIP)
Insider Transaction List (Q2 2022)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Apr 27
2022
|
Robert E. Brown Jr |
BUY
Grant, award, or other acquisition
|
Direct |
10,049
+17.01%
|
-
|
|
Apr 27
2022
|
Patrick D Walsh Director |
BUY
Grant, award, or other acquisition
|
Direct |
10,049
+13.67%
|
-
|
|
Apr 27
2022
|
Jeanne Thoma Director |
BUY
Grant, award, or other acquisition
|
Direct |
10,049
+25.52%
|
-
|
|
Apr 27
2022
|
Antonio R Pera Director |
BUY
Grant, award, or other acquisition
|
Direct |
10,049
+25.24%
|
-
|
|
Apr 27
2022
|
David Nash Director |
BUY
Grant, award, or other acquisition
|
Direct |
10,049
+24.07%
|
-
|
|
Apr 27
2022
|
Thomas Haughey Director |
BUY
Grant, award, or other acquisition
|
Direct |
10,049
+19.98%
|
-
|
|
Apr 27
2022
|
Nikhil Lalwani PRESIDENT & CEO |
BUY
Grant, award, or other acquisition
|
Direct |
33,352
+10.46%
|
-
|
|
Apr 27
2022
|
Stephen P. Carey SVP & CFO |
BUY
Grant, award, or other acquisition
|
Direct |
11,291
+7.15%
|
-
|
|
Apr 27
2022
|
James G. Marken SVP OPS & PROD DEV |
BUY
Grant, award, or other acquisition
|
Direct |
6,644
+4.67%
|
-
|
|
Apr 27
2022
|
Christopher Mutz HEAD OF RARE DISEASE |
BUY
Grant, award, or other acquisition
|
Direct |
6,476
+13.68%
|
-
|
|
Apr 27
2022
|
Ori Gutwerg SVP, GENERICS |
BUY
Grant, award, or other acquisition
|
Direct |
6,476
+14.68%
|
-
|
|
Apr 10
2022
|
Stephen P. Carey SVP & CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
4,534
-3.24%
|
$131,486
$29.91 P/Share
|
|
Apr 10
2022
|
James G. Marken SVP OPS & PROD DEV |
SELL
Payment of exercise price or tax liability
|
Direct |
1,878
-1.43%
|
$54,462
$29.91 P/Share
|
|
Apr 06
2022
|
James G. Marken SVP OPS & PROD DEV |
SELL
Payment of exercise price or tax liability
|
Direct |
337
-0.26%
|
$9,773
$29.69 P/Share
|
|
Apr 06
2022
|
Stephen P. Carey SVP & CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
912
-0.65%
|
$26,448
$29.69 P/Share
|